We evaluated the impact of clinical (age, clinical stage before NC, clinical ALNs status before and after surgery, clinical response), pathological (histological grade, tumor size, pathology, axillary lymph node status, and pathological response) and immunohistochemical (ER, PR, Ki-67 and HER-2 protein expression before and after surgery) features on disease free survival (DFS) and overall survival (OS). The gene discussed is PGR; the disease is neoplasm.